Search Result

Results for "

Receptor for Advanced Glycation end products

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (4) Aldose Reductase (2) Amyloid-β (4) Apoptosis (3) Autophagy (2) Caspase (2) CCR (1) EAAT (1) Interleukin Related (2) Isotope-Labeled Compounds (2) Mitophagy (2) Neurokinin Receptor (2) Reactive Oxygen Species (ROS) (1) Reference Standards (2) TNF Receptor (2) Toll-like Receptor (TLR) (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (5) Endocrinology (6) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (5)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Ligands for Target Protein for PROTAC Ligands for E3 Ligase PROTAC-Linker Conjugates for PAC Drug-Linker Conjugates for ADC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50682

Azeliragon Maximum Cited Publications 13 Publications Verification TTP488; PF-04494700	Amyloid-β	Neurological Disease Cancer
Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-147329

RAGE 229	Transmembrane Glycoprotein	Metabolic Disease
RAGE 229 is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1) .

HY-129611

Bromelain	Apoptosis	Inflammation/Immunology Cancer
Bromelain is an anti-inflammatory agent derived from pineapple stem that acts through down-regulation of plasma kininogen, inhibition of Prostaglandin E2 expression, degradation of advanced glycation end product receptors and regulation of angiogenic biomarkers as well as antioxidant action upstream in the COX-pathway . Bromelain exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Bromelain also possesses some anticancerous activities and promotes apoptotic cell death .

HY-B1392

Esmolol hydrochloride 3 Publications Verification	Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor	Cardiovascular Disease Endocrinology Cancer
Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol hydrochloride attenuates post resuscitation myocardial dysfunction. Esmolol hydrochloride improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

HY-50682A

Azeliragon dihydrochloride TTP488 dihydrochloride; PF-04494700 dihydrochloride	Amyloid-β	Neurological Disease Cancer
Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB) .

HY-50682R

Azeliragon (Standard)	Amyloid-β Reference Standards	Neurological Disease Cancer
Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-50682S

Azeliragon-d9 TTP488-d₉; PF-04494700-d₉	Isotope-Labeled Compounds Amyloid-β	Neurological Disease Endocrinology
Azeliragon-d₉ (TTP488-d₉) is the deuterium labeled Azeliragon (HY-50682). Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-178926

RAGE406R	CCR TNF Receptor Interleukin Related	Metabolic Disease Inflammation/Immunology Endocrinology
RAGE406R is an orally active RAGE-DIAPH1 interaction antagonist. RAGE406R can bind to ctRAGE and prevent the formation of the RAGE-DIAPH1 complex and inhibit its interaction. RAGE406R can reduce the expression of CCL2, TNF, and IL-6 in THP1 cells. RAGE406R suppresses delayed-type hypersensitivity in T2D mice. RAGE406R can be used for the study of diabetes .

HY-B1392A

Esmolol	Adrenergic Receptor Caspase Apoptosis Aldose Reductase Neurokinin Receptor	Cardiovascular Disease Endocrinology Cancer
Esmolol is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol exerts its antiarrhythmic effect by activating Neurokinin 1 Receptor. Esmolol attenuates post resuscitation myocardial dysfunction. Esmolol improves diabetic wound healing by inhibiting aldose reductase and the production of advanced glycation end products and promoting fibroblast migration. Esmolol can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

HY-B1392R

Esmolol hydrochloride (Standard)	Reference Standards Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology Cancer
Esmolol hydrochloride (Standard) is the analytical standard of Esmolol hydrochloride (HY-B1392).This product is intended for research and analytical applications. Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating *Neurokinin 1 Receptoraldose reductase* and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

HY-B1392S

Esmolol-d7 hydrochloride	Isotope-Labeled Compounds Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology Cancer
Esmolol-d₇ hydrochloride is the deuterium labeled Esmolol hydrochloride (HY-B1392). Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating *Neurokinin 1 Receptoraldose reductase) and the production of advanced* glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

HY-W585874

Nε-(Carboxyethyl)lysine	EAAT	Neurological Disease
Nε-(Carboxyethyl)lysine is an advanced glycation end product (AGE). Nε-(Carboxyethyl)lysine causes cross-linking between proteins, affects the structure and function of proteins, and leads to protein denaturation. Nε-(Carboxyethyl)lysine binds to RAGE receptors, affects cell signaling, regulates processes such as inflammatory response, cell proliferation and apoptosis. Nε-(Carboxyethyl)lysine affects glutamate transporter, reduces glutamate uptake and S100B protein secretion, affects neurotransmission in the nervous system, and exhibits diabetic-related neurotoxicity .

HY-124750

NecroX-7	TNF Receptor Interleukin Related Toll-like Receptor (TLR) Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology
NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research .

Cat. No.	Product Name	Chemical Structure

HY-50682S

Azeliragon-d9
Azeliragon-d₉ (TTP488-d₉) is the deuterium labeled Azeliragon (HY-50682). Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) . Azeliragon also can cross the blood-brain barrier (BBB) .

HY-B1392S

Esmolol-d7 hydrochloride
Esmolol-d₇ hydrochloride is the deuterium labeled Esmolol hydrochloride (HY-B1392). Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating *Neurokinin 1 Receptoraldose reductase) and the production of advanced* glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

Esmolol-d7 hydrochloride

Esmolol-d₇ hydrochloride is the deuterium labeled Esmolol hydrochloride (HY-B1392). Esmolol hydrochloride is an ultra-short-acting cardioselective β1-adrenergic blocker. Esmolol hydrochloride exerts its antiarrhythmic effect by activating Neurokinin 1 Receptoraldose reductase) and the production of advanced glycation end products and promoting fibroblast migration. Esmolol hydrochloride can be used to study cardiac diseases such as arrhythmias and diabetic foot ulcers .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.